References
1. Lamy T, Moignet A, Loughran TP, Jr. LGL leukemia: from pathogenesis to treatment.Blood. 2017;129(9):1082-1094.
2. Sanikommu SR, Clemente MJ, Chomczynski P, et al. Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). Leuk Lymphoma. Feb 2018;59(2):416-422.
3. Moignet A, Lamy T. Latest Advances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia. Am Soc Clin Oncol Educ Book. May 23 2018;38:616-625.
4. Dong N, Castillo Tokumori F, Isenalumhe L, et al. Large Granular Lymphocytic Leukemia - a Retrospective Study of 319 Cases. Am J Hematol. Apr 5 2021.
5. Poh C, Arora M, Ghuman S, Tuscano J. Belinostat in Relapsed/Refractory T-Cell Large Granular Lymphocyte Leukemia. Acta Haematol. 2021;144(1):95-99.
6. Awada H, Mahfouz RZ, Kishtagari A, et al. Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies.British Journal of Haematology. 2020;188(6):924-929.
7. Saunthararajah Y. Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes. Hematology Am Soc Hematol Educ Program.2013;2013:511-521.
8. Saunthararajah Y, Hillery CA, Lavelle D, et al. Effects of 5-aza-2’-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood. Dec 1 2003;102(12):3865-3870.
9. Saunthararajah Y, Sekeres M, Advani A, et al. Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. J Clin Invest. Mar 2 2015;125(3):1043-1055.
10. Loughran TP, Jr., Kadin ME, Starkebaum G, et al. Leukemia of large granular lymphocytes: association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. Ann Intern Med. Feb 1985;102(2):169-175.
11. Durrani J, Awada H, Kishtagari A, et al. Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. Leukemia. 2020/03/01 2020;34(3):957-962.
12. Shi M, He R, Feldman AL, et al. STAT3 mutation and its clinical and histopathologic correlation in T-cell large granular lymphocytic leukemia. Human Pathology.2018/03/01/ 2018;73:74-81.
13. Barilà G, Teramo A, Calabretto G, et al. Stat3 mutations impact on overall survival in large granular lymphocyte leukemia: a single-center experience of 205 patients. Leukemia. 2020/04/01 2020;34(4):1116-1124.
14. Teramo A, Gattazzo C, Passeri F, et al. Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia. Blood. May 9 2013;121(19):3843-3854, S3841.